哮喘儿童血清sICAM-1及Eotaxin的含量变化及意义

目的探讨支气管哮喘患儿血清可溶性细胞间黏附分子-1（sICAM-1）和嗜酸性粒细胞趋化蛋白（Eotaxin）水平的变化及临床意义。方法随机选择2006年1月至2007年1月深圳市宝安区妇幼保健院哮喘专科收治的哮喘患儿急性发作期35例、缓解期25例、正常对照组25例,采用酶联免疫吸附试验（ELISA）测定3组血清sICAM-1和Eotaxin水平。结果急性发作组sICAM-1及Eotaxin较缓解组、正常对照组明显升高（P〈0.01）,缓解组sICAM-1较对照组显著升高（P〈0.01）,缓解组Eotaxin与对照组无显著差异。sICAM-1及Eotaxin重度发作组明显高于轻中度组（P〈0.01）。结论sICAM-1及Eotaxin水平与哮喘病情变化一致,可以用来监测哮喘的气道炎性反应状况,判断治疗效果及预后。

The changes and significance of sICAM-1 and Eotaxin level in asthma children serum

Objective To evaluate clinical applications of sICAM-1 and Eotaxin level in asthma children serum. Methods Randomly chosen from January 2006 to January 2007 in asthma specialty of Maternal and Child Healtheare Hospital of Baoan, asthmatic acute attack patients are 35 cases, athmatie remission are 25 cases, and normal control group are 25 cases. Enzyme-linked immunosorbent test （ELISA） is used to measure the sICAM-1 and Eotaxin level in 3 groups of serum. Results The sICAM-1 and Eotaxin level of athmatic acute attack group is significantly higher than that of athmatic remission group and normal control group（ P 〈 0.01 ）. The sICAM-1 level of athmatic remission group is significantly higher than that of normal control group （ P 〈 0. 01 ）. The Eotaxin level of athmatic remission group had no significant difference with the control group. The sICAM-1 and Eotaxin level of severe attack group is obviously higher than mild-to-moderate group（P 〈 0. 01 ）. Conclusion The sICAM-1 and Eotaxin level changes according to asthma condition ,which can be used to monitor the airway inflammation ,judge therapeutic effect and prognosis.